<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03392103</url>
  </required_header>
  <id_info>
    <org_study_id>HCCSC G03</org_study_id>
    <nct_id>NCT03392103</nct_id>
  </id_info>
  <brief_title>Adjuvant IMRT With Concommitant Raltitrexed Chemotherapy for Locally Advanced Gastric Cancer After D0/D1 Radical Resection</brief_title>
  <official_title>Adjuvant IMRT With Concommitant Raltitrexed Chemotherapy for Locally Advanced Gastric Cancer After D0/D1 Radical Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhongnan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhongnan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether raltitrexed concurrent with IMRT is safe,&#xD;
      tolerable and effective in the treatment for patients with local-advanced gastric cancer&#xD;
      after D0/D1 radical resection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The ratio of patients occured Grade 3 or higher adverse events</measure>
    <time_frame>From the first day of the concurrent chemoradiotherapy (CRT) to the 180th day after CRT.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>2-year local-regionally recurrence rate</measure>
    <time_frame>2 year</time_frame>
    <description>The probability of locally and/or regionally recurrence at 2 year after CRT on imaging or pathological examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year local-regionally recurrence rate</measure>
    <time_frame>3 year</time_frame>
    <description>The probability of locally and/or regionally recurrence at 3 year after CRT on imaging or pathological examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year disease-free survival probability</measure>
    <time_frame>2 year</time_frame>
    <description>The probability of staying free from recurrence at 2 year after CRT on imaging or pathological examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year disease-free survival probability</measure>
    <time_frame>3 year</time_frame>
    <description>The probability of staying free from recurrence at 3 year after CRT on imaging or pathological examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year overall survival probability</measure>
    <time_frame>2 year</time_frame>
    <description>The probability of staying alive at 2 year after CRT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year overall survival probability</measure>
    <time_frame>3 year</time_frame>
    <description>The probability of staying alive at 3 year after CRT.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>postoperative CRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>postoperative CRT: Treatment including postoperative radiotherapy (IMRT) with concurrent chemotherapy of Raltitrexed. Radiotherapy will be delivered to a planning target volume with a dose of 45-50.4Gy (1.8-2.0Gy daily) using with Intensity-Modulated Radiotherapy technique. During the radiation treatment, concurrent chemotherapy will be delivered (Raltitrexed, intravenous infusion, 3 mg/m2, on w1 and w4).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltitrexed</intervention_name>
    <description>concurrent chemotherapy</description>
    <arm_group_label>postoperative CRT</arm_group_label>
    <other_name>Raltitrexed Injectable Solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>postoperative radiotherapy</intervention_name>
    <description>concurrent postoperative radiation therapy</description>
    <arm_group_label>postoperative CRT</arm_group_label>
    <other_name>adjuvant radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed consent signed.;&#xD;
&#xD;
          2. Age: 18-70 years old, sex is not restricted;&#xD;
&#xD;
          3. Pathologically diagnosed as gastric adenocarcinoma or gastroesophageal junction&#xD;
             adenocarcinoma; did not receive neoadjuvant chemotherapy or radiotherapy before&#xD;
             surgery;received the 2-3 cycles of chemotherapy of FOLFOX regimens or 1-2 cycles of&#xD;
             XeLOX or SOX regimens after operation;&#xD;
&#xD;
          4. Received D0 or D1 operation, no tumor residual (R0);&#xD;
&#xD;
          5. Postoperative pathological stage of pT3N0, pT4N0 or any T, N1-2, without distant&#xD;
             metastatic disease;&#xD;
&#xD;
          6. ECOG 0-2;&#xD;
&#xD;
          7. Normal blood analysis: WBC≥3.5 X 109/L, GRAN≥2.0 X 109/L = 2, Hb≥90g/L, PLT≥100 X&#xD;
             109/L;&#xD;
&#xD;
          8. Liver function: ALT or AST is less than or equal to 2.5 times of the normal high value&#xD;
             (ULN); bilirubin is less than 1.5*ULN, serum APK is less than 2.5 * ULN;&#xD;
&#xD;
          9. Renal function: serum creatinine is less than 1.5 * ULN, and creatinine clearance rate&#xD;
             is more than 60ml/min;&#xD;
&#xD;
         10. No previous chemotherapy or radiation therapy history;&#xD;
&#xD;
         11. No organ transplant history;&#xD;
&#xD;
         12. Urine pregnancy test results are negative for women of childbearing age in the first 7&#xD;
             days and not in lactation before treatment;&#xD;
&#xD;
         13. Men and women of childbearing age agreed to adopt reliable methods of contraception&#xD;
             for 30 days before , during and after the course of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received D2 radical operation;&#xD;
&#xD;
          2. Tumor residual (R1/R2);&#xD;
&#xD;
          3. There was found evidence of distant metastasis (M1) or suspicious metastasis after&#xD;
             examination;&#xD;
&#xD;
          4. Other cancer history, except skin basal cell carcinoma or cervix in-situ carcinoma;&#xD;
&#xD;
          5. Previously received chemotherapy or other systemic anticancer therapy, including&#xD;
             cytotoxic drugs, targeted drugs; or had received abdominal radiotherapy;&#xD;
&#xD;
          6. Anticipate other clinical trials in four weeks before enrollment.&#xD;
&#xD;
          7. Severe complication, such as acute myocardial infarction in 6 months, uncontrolled&#xD;
             diabetes, severe cardiac arrhythmia, etc.&#xD;
&#xD;
          8. Drug abuse history or alcohol addiction;&#xD;
&#xD;
          9. Active infection existed.&#xD;
&#xD;
         10. with severe malnutrition or severe anemia;&#xD;
&#xD;
         11. Human immunodeficiency virus (HIV) infection;&#xD;
&#xD;
         12. Pregnancy (confirmed by serum or urine beta -HCG test) or during lactation;&#xD;
&#xD;
         13. Can not tolerate this study or may be allergic to the drug used in this study;&#xD;
&#xD;
         14. Persons who have no or restricted capacity for civil conduct; or have mental illness,&#xD;
             whom the researchers believe can not fully understand the possible complications of&#xD;
             this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fuxiang Zhou, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Wuhan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing Dai, M.D.</last_name>
    <phone>+86（0）2767813155</phone>
    <email>daijing1116@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ling Xai, M.D.</last_name>
    <phone>+86（0）2767813155</phone>
    <email>22425583@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongnan Hopital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fuxiang Zhou, M.D.</last_name>
      <phone>+86（0）2767813155</phone>
      <email>fuxiang.zhou@whu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Jing Dai, M.D.</last_name>
      <phone>+86（0）2767813155</phone>
      <email>daijing1116@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>December 19, 2017</study_first_submitted>
  <study_first_submitted_qc>January 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2018</study_first_posted>
  <last_update_submitted>January 4, 2018</last_update_submitted>
  <last_update_submitted_qc>January 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhongnan Hospital</investigator_affiliation>
    <investigator_full_name>Zhou Fuxiang</investigator_full_name>
    <investigator_title>Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Raltitrexed</keyword>
  <keyword>IMRT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltitrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

